{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lumos Pharma, Inc.
Is Lumos Pharma, Inc. technically bullish or bearish?
As of October 1, 2023, there is not enough technical data on Lumos Pharma, Inc. to determine if it is bullish or bearish.
Who are in the management team of Lumos Pharma, Inc.?
As of March 2022, the management team of Lumos Pharma, Inc. includes Richard Hawkins (Chairman, President, CEO), Dr. Thomas Raffin (Lead Independent Director), Dr. Nicholas Vahanian, Dr. Emmett Cunningham, Mr. Chad Johnson, and Mr. Kevin Lalande (all Independent Directors). They oversee the company's strategic direction and operations.
What does Lumos Pharma, Inc. do?
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for rare diseases, with a market cap of $37.53 million and quarterly net sales of $1 million. As of September 2024, it reported a net loss of $7 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
